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Abstract
Background: The graphical content of the Medicines Package Inserts (MPIs), such as illustrations and typo-
graphic features should be legible and appropriate, as required by international pharmaceutical regulations.
Objectives: To study: (1) the frequency and type of MPIs’ key graphic elements, (2) their compliance with
regulations and (3) how educated people understand them.
Methods: Descriptive study: characterisation of the graphical content of 651 MPIs. Usability study: illus-
trations and tables (purposively selected) were evaluated with questionnaires in three groups of humanities
undergraduates (illustrations only, illustrations plus text and text only).
Results: Descriptive study: illustrations and tables were respectively identiﬁed in 6.3% and 11.8% of the
MPIs. The illustrations were mainly related to how to take/use the medicine. Non-recommended graphical
representations were found (e.g. italic or underline). Usability test: legibility issues were identiﬁed, espe-
cially for the group of isolated illustrations.
Discussion & conclusions: The scarce use of illustrations and tables possibly affected the legibility of the
MPIs. Compulsory legibility tests are needed to guarantee the MPIs’ proper use, thus contributing to a
safe use of medicines. Overall, this study highlighted the need to carefully revise/assess the MPIs’ design
and probably increase health information experts’ awareness on this issue.
Keywords: communication, consumer health information; health information needs; patient information
Key messages
• Although the use of illustrations supports patients’ comprehension, satisfaction, adherence and
recall, they were scarcely used in a large sample of Portuguese package inserts.
• Usability issues were found concerning the illustrations and tables of medicinal package inserts an
educated people, which suggest greater problems for the low-literate groups.
• This study raises the question of the relevance of the quality assessment and legibility assurance of
the medicinal packages inserts.
• It is advisable to update the regulations on the use of graphic elements and to develop methods for
approving legibility of package inserts.
• Specialists in health information and related areas are likely to contribute to the improvement of
the graphic content and readability of the package inserts.
Introduction
Users’ awareness of health information materials
and their reaction patterns, such as satisfaction,
reassurance or worry, as well as their ability to use
this information (i.e. self-efﬁcacy) vary not only
between individuals but also when the readability
and design characteristics of these materials are
concerned.1–6 This is speciﬁcally relevant for the
low-literate patients, since those with limited
comprehension of health materials are more likely
*Correspondence: Carla Maria Pires, Research Institute for Medicines and
Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Av.
Prof. Gama Pinto, 1649-003 Lisboa, Portugal. E-mail: cmbpires@ff.ul.pt
© 2015 Health Libraries Group
Health Information & Libraries Journal, 33, pp. 121–139 121
DOI: 10.1111/hir.12128
to experience poor health related outcomes,
including fatalities.4–7
Health information materials and, particularly,
Medicines Package Inserts (MPIs) are very relevant
for consumers, patients and health professionals as a
way of transmitting safety and efﬁcacy information
about medicines.8–10 In a study by Hamrosi at al.
(carried out in 2009), a national sample of
Australian consumers, community pharmacists and
general practitioners were questioned about their
preferences on sources of medicine information.
The ﬁndings of this study revealed that, 68% of the
consumers, 34% of the pharmacists and 23% of the
general practitioner preferred the MPIs as sources of
medicine information. In this study, the favourite
information sources for the pharmacists and general
practitioners, respectively, were the consumer
medicine information and the oral information.6
MPIs are available inside all the packages of
medicinal products in the European Union member
states,9 and must be designed and tested according
to the requirements of the Guideline on the
Readability of the Labelling and Package
Leaﬂet.10 In accordance to this guideline and
current scientiﬁc literature, MPIs need to be
clearly understood in an appropriate timeframe by
patients, including illustrations and tables.10–14
Illustrations and symbols are speciﬁcally
allowed to be used in MPIs by medicines
agencies, such as the European Medicine Agency
(EMA, Europe), the Food and Drug
Administration (FDA, United States of America)
and the Therapeutic Goods Administration (TGA,
Australia).10,15,16 Illustrations should reﬂect the
information accurately and unambiguously, and
should not be suggestive of non-approved
indications.10,11,16 In addition, the medicines
regulatory authorities also established some design
and layout recommendations for the MPIs,9,17 such
as text orientation (portrait), bullet points (left
alignment), titles (centered, bold, capital letters),
heading (bold, capital letters), subheadings (bold,
normal letters), tables (single line style).17
Besides the above mentioned regulatory
requirements, there are scientiﬁc studies
speciﬁcally done on the positive and negative
aspects of using illustrations18–22 or other graphic
elements in the MPIs and other written documents
(e.g. bullets or headings).20,23–27 Illustrations
increase attention, comprehension and recall of
health materials, this being particularly relevant for
the low-literate patients,4,5 and especially if
pictures are associated with written text or oral
instructions.11,14,18,20,28,29 For instance, in the US
Sojourner et al.20 used three groups of participants
(undergraduates, younger adults and elders) to
evaluate their satisfaction and recall of written
information in three forms (text only, pictures only
or text with pictures); overall, the text with pictures
was better rated and recalled. On the other hand,
caution is recommended when using illustrations in
MPIs because, in certain cases, illustrations are not
helpful or appropriate.11,21,30,31 For instance, in a
study to evaluate common warning proprieties,
Webb et al.21 found that in the majority of the
cases pictures were confusing for the participating
patients from a general internal medicine clinic in
United States, with around half of them presenting
limited literacy. Moreover, the use of bold, bullets
and headings are among the common design
strategies to facilitate the reading of prose
information.17,23,24,27,33 Oppositely, the use of
underline, italics, hyphenated lists, headings with
text boxes and capitalised letters in the body text
are not recommended (e.g. the use of capitalised
sentences in the body text), because these items do
not favour text legibility.17,23,24,27,33 For instance,
boxed headings must not appear in the ﬁnal printed
packaging materials.17
Given the current regulatory requirements and the
existing body of literature,1–33 it was considered
relevant to characterise the graphic elements in a
representative sample of Portuguese MPIs, as well
as to evaluate the level of potential users’
comprehension regarding illustrations and tables
from the sampled MPIs. In this context, two
exploratory studies were developed (Study A and
B): Study A aimed to a) characterise (quantitatively
and qualitatively) all the following key graphical
elements, i.e. ﬁgures, pictograms, tables and other
graphical elements (OGE), such as bold or bullet
points in a representative sample of Portuguese
MPIs, and b) assess the compliance of these
graphical elements with pharmaceutical regulations;
and Study B (a usability test) aimed to assess the
comprehension of purposively selected illustrations
and tables within a group of non health care
educated people.
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Methods
Study A – The descriptive study
A cross-sectional study design was followed: all the
MPIs of branded medicines included in the National
Prescribing Guide and also from the three
therapeutic groups of medicines most consumed in
Portugal (2009 health market data), i.e.
cardiovascular (CS), central nervous (CNS) and
musculoskeletal systems (MS) were selected.34,35
The MPIs of the generic medicines were not
selected because these MPIs are very similar or
even equal to the MPIs of branded medicines.9,36
The MPIs were identiﬁed in a public medicine
database (Infomed) between January and March
2012.37
For this study, it was deﬁned that pictograms
were illustrations composed of at least two images,
ﬁgures were illustrations composed of only one
image,38 tables were graphic representations with
rows and columns, and the lists or iterations were
groups of words or sentences preceded by
hyphens, bullet points or other graphic elements.
In addition, other graphic elements (OGE) were
also identiﬁed and quantiﬁed in the sampled MPIs.
The studied OGE were: bold font, italics,
underline, capitalised letters in the body text (the
titles and sub-tittles were not evaluated, i.e. only
the existence of uppercase in the body text was
registered), headings with text boxes, associations
of the previous graphic elements, other graphic
elements used to highlight information (e.g.
symbols, such as an arrow to highlight important
facts at the end of the sections), and the case
format of the section titles (uppercase, lowercase
or both). The data collection was based on the
application of a checklist (Appendix A), which
facilitated the identiﬁcation and quantiﬁcation of
ﬁgures, pictograms, tables, lists/iterations and OGE
in the sampled MPIs.
The occurrence of ﬁgures, pictograms, tables,
lists/iterations and OGE (Appendix A: checklist)
was also quantiﬁed in each one of the 6 sections
of the MPI: 1) What is X and what is used for
(X = medicinal product name), 2) What you need
to know before you <take> <use> X, 3) How to
<take> <use> X, 4) Possible side effects; 5) How
to store X and 6) Contents of the package and
other information, as stated in the Quality Review
of Documents (QRD) template.32,39 The QRD
template is used by applicants and marketing-
authorisation holders to standardise the information
of MPIs, as in the case of the medicines with a
single marketing authorisation valid in all
countries of the European Union (medicines
approved via a centralised authorisation procedure
by the EMA).40 In the case of these medicines, a
translated version of the same MPI is used in all
European countries.32,39,40
Qualitative descriptors were deﬁned to classify
the content of the illustrations and the topics
associated with the use of graphic elements. The
checklist and the qualitative descriptors (Table 1)
were developed considering the Portuguese and
European regulations9,10,17,32,33,36 and, in particular,
the terminology of the QRD template (version 8).32
The study data were submitted to a quality
control procedure according to the principles of the
NBR 5425 norm.41 First, all variables of the study
were collected in an MS Excel database and,
second, around 15% of the MPIs were randomly
selected and re-analysed to conﬁrm data
consistency. This procedure was performed by a
single researcher.
Study B – The usability study
A cross-over study design was used: three
independent self-administered questionnaires
(Appendix B) were used to assess participants’
comprehension of two ﬁgures, two pictograms and
two tables. These illustrations and tables were
purposively selected from the sampled MPIs based
on the criteria of previous studies,11,18,20,28,29,42
and after the consensus cycles within the research
team. The initial inclusion criteria was based on
the selection of all illustrations and tables related
to how to take/use the medicine, because in
accordance to previous studies, this theme is
relevant for patients, potential users of medicines
and health professionals.18,25,43 In a second step,
the following illustrations were purposively
selected: two ﬁgures on the administration of
tablets (instructions to not break a tablet or on
how to split a pill), because tablets are the most
commonly consumed pharmaceutical forms,35 and
two pictograms covering other types of
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Table 1 Qualitative descriptors of the graphic elements
Classification
Therapeutic groups
CNS (309 MPIs)
n (%)*
CS (179 MPIs)
n (%)*
MS (163 MPIs)
n (%)*
1. Qualitative descriptors of the Figures:
How to <take> <use> 7 (100) 2 (100) 3 (33.3)
How it looks like 0 (0) 0 (0) 3 (33.3)
Precautions 0 (0) 0 (0) 3 (33.3)
Total of figures 7 (100) 2 (100) 9 (100)
2. Qualitative descriptors of the Pictograms:
How to <take> <use> 17 (100) 2 (100) 4 (100)
Total of pictograms 17 (100) 2 (100) 4 (100)
3. Qualitative descriptors of the Tables:
ADR (description + frequency) 4 (9.8) 8 (42) 2 (11.8)
ADR frequency 5 (12.2) 2 (10.5) 4 (23.5)
Precautions 1 (2.4) 0 (0) 0 (0)
Interactions 1 (2.4) 1 (5.3) 0 (0)
Posology 19 (46.3) 4 (21) 10 (58.8)
Fargerstr€om Test 2 (4.9) 0 (0) 0 (0)
Marketing Authorisation Holders 9 (22) 4 (21.1) 1 (5.9)
Total of tables 41 (100) 19 (100) 17 (100)
4. Qualitative descriptors of all Lists/Iterations:
What is used for 54 (5.1) 51 (7.8) 65 (12.6)
Mechanism of action 0 (0) 6 (0.9) 2 (0.4)
Do not use 234 (22.2) 147 (22.5) 128 (24.8)
Take special care 187 (17.7) 107 (16.4) 87 (16.7)
Interactions 130 (12.3) 77 (11.8) 51 (9.9)
Pregnancy 19 (1.8) 7 (1.1) 7 (1.4)
Breast feeding 7 (0.7) 8 (1.2) 4 (0.8)
Fertility 0 (0) 0 (0) 1 (0.2)
Driving 2 (0.2) 2 (0.3) 1 (0.2)
Posology 63 (6) 29 (4.4) 19 (3.6)
Overdose 31 (2.9) 4 (0.6) 5 (1)
Routine examinations 4 (0.4) 2 (0.3) 4 (0.8)
Administration form 22 (2.1) 19 (2.9) 10 (1.9)
ADR 122 (11.6) 73 (11.2) 30 (5.8)
Conservation 10 (0.9) 15 (2.3) 4 (0.8)
Packaging 4 (0.4) 3 (0.5) 4 (0.8)
Physical aspect 6 (0.6) 4 (0.6) 0
Composition 159 (15.1) 100 (15.2) 95 (18.3)
Total of Lists/Iterations 1054 (100) 654 (100) 517 (100)
5. Qualitative descriptors of the OGE:
Bold 45 (16.6) 19 (15.1) 26 (19)
Headings with text boxes† 1 (0.4) 1 (0.8) 0
Italic† 26 (9.6) 11 (8.7) 12 (8.8)
Capitalised letters in the body text†,‡ 142 (52.4) 67 (53.2) 77 (56.2)
Graphic elements associations (a mix of the previous) 0 1 (0.8) 1 (0.7)
Underline† 53 (19.5) 27 (21.4) 21 (15.3)
Use of one graphic element to highlight and/or
summarise key information
4 (1.5) 0 (0) 0 (0)
Total of OGE 271 (100) 126 (100) 137 (100)
6. Format of letters in MPIs titles:
All capital letters 233 (75.4) 128 (71.5) 115 (70.6)
(continued)
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administration instructions: one pictogram on
syrup administration of a prescription for
paediatric medicines, because the caregivers of
children manifest a preference for simple and clear
written materials,3 and one pictogram on the
transdermal system application of a OTC
medicine, because OTC may be acquired without
health professionals’ mediation.9,23,36 In addition,
the tables with the highest number of columns and
rows were selected, because these tables are likely
to comprise more information and, thus are likely
to be more complex to read and interpret. All
evaluated illustrations and tables (two ﬁgures, two
pictograms and two tables) are presented in
Appendix B. In addition, open questions were
used to evaluate participants’ health knowledge,
functioning also as an exclusion criteria. These
questions were on: (1) participants’ previous health
training (trainers or trainees); (2) any work
experience in the health sector, including
caregiving and/or (3) any other situation
susceptible of contributing to the increase in health
knowledge. All the participants answered
negatively to the previous questions, thus none
was excluded. Demographic data were also
collected (age, gender and years of study).
Study participants were conveniently recruited
from undergraduate humanities courses, in April
2013. These participants were selected: (1) to
avoid expertise bias, because no speciﬁc health
knowledge is expected from them, for instance in
comparison to the undergraduates of medicine,
nursing or pharmacy; and also (2) to obtain an
appropriate use of the information,4,5,8 because, it
was considered that university students are more
likely to have a higher literacy level than the
general population. Furthermore, according to the
last Portuguese Census (2011), around 70% of the
Portuguese population only have the 9th grade or
less,44 and according to the last national health
literacy study (2014), 61.4% of all the participants
presented problematic or inadequate health
literacy.45 In this context, it was assumed that if
usability issues were found in this study, even
worse results would possibly be expected from the
general Portuguese population.
Table 1. (continued)
Classification
Therapeutic groups
CNS (309 MPIs)
n (%)*
CS (179 MPIs)
n (%)*
MS (163 MPIs)
n (%)*
Capital letters only at the beginning† 42 (13.6) 21 (11.7) 17 (10.4)
Mix of upper and lower case letters† 34 (11) 30 (16.8) 31 (19)
Total of analysed headings§ 309 (100) 179 (100) 163 (100)
MPIs, medicines package inserts; CNS, central nervous system; CS, cardiovascular system; MS, musculosketal system; n, num-
ber; OGE, other graphical elements; ADR, adverse drug reactions.
Precautions: The description of the safety measures on how to use the medicines (e.g. type of actions in case the patient suf-
fer from a certain disease).32. ADR – Adverse drug reactions: A response to a medicinal product which is noxious and unin-
tended; usually occurring at doses normally used in man.9. ADR frequency: The probability of occurring a certain ADR (e.g. 1
in 1000 individuals).32. Interactions: Description of the possible interactions between the medicine described in the MPI with
other medicine(s) or other types of substance(s) (e.g. an enhanced or decreased effect of a drug).32. Posology: The quantity
and frequency of administration of the medicine to have a therapeutic effect (dosage information).32. Fargerstr€om Test: A
test to evaluate the smoker’s degree of dependence on nicotine. Marketing Authorization Holders: The marketing authoriza-
tion holder (e.g. a company) is the responsible for all aspects of the product (e.g. the efficacy and safety of the medi-
cine).9,36. Driving: The description of possible negative effects on the ability to drive and use machines and the required
actions if any undesirable effect occur.32. Overdose: An hazard dose of a medicine – description of the type of symptoms
and necessary actions.32
*The percentages were calculated in relation to the number of MPIs of each therapeutic group.
†Graphic elements non-recommended in the pharmaceutical regulations.10,17,33
‡The titles and sub-tittles were not evaluated in this assessment, i.e. only the existence of uppercase in the body text was
registered.
§It was classified the first heading of all MPIs.
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Participants were randomly assigned to one of
the three groups: Group 1 (only isolated
illustrations were evaluated); Group 2 (the same
illustrations used in Group 1 plus an excerpt of the
text were evaluated) and Group 3 (only the
excerpt of texts used in Group 2 without the
illustrations were evaluated). This methodological
design was deﬁned to separately identify possible
readability and legibility issues, respectively in the
groups of isolated illustrations (ﬁgures or
pictograms) (Group 1) or texts (Group 3), while
conﬁrming the greater intelligibility of text plus
image association (Group 3). Furthermore, this
methodology was already used in other
studies.11,18,20,28,29 In particular, the excerpts of
text were speciﬁcally matched with the text of the
MPIs about the illustrations given. Groups 1, 2
and 3 were respectively composed of 17, 14 and
14 participants. The sample sizes were
conveniently deﬁned based on previous studies on
the same research topic.10,11,18,46
All the questionnaires were similar in their
structure and used both open and closed questions
(Appendix A). The open questions were used to
collect participants’ general interpretation of the
illustrations and the tables selected, where the
questions about the tables asked participants to
consult the table and indicate the right dosage
(expressed in ml) of a paediatric syrup. The close
questions were based on a Likert scale, used for
rating the table layouts. All collected data were
completely anonymous and conﬁdential.
Statistical analysis
The statistical data analysis was performed using
SPSS (IBM-SPSS version 19.0, Chicago, IL).
Besides the general evaluations of the descriptive
statistic (e.g. percentage, median, mode, etc.), the
Kruskal–Wallis (K–W) test was used to perform
comparisons between more than two groups. This
test was used to evaluate the difference between
the proportions of: (1) different graphic elements
in the MPIs from the three therapeutic groups
(CNS, CS and MS) (Study A) and (2) the
participants’ correct or incorrect interpretations on
the evaluated illustrations between the three
groups: illustrations only, illustrations plus text
and text only (Study B). When applicable, the
non-parametric test Mann–Whitney U-test, was
also used, speciﬁcally for comparisons between
the two groups. Non-parametric tests were
selected, because most study variables were
nominal, i.e. presence/absence of a certain
graphical element in the sampled MPIs or the
classiﬁcation of correct/incorrect participants’
replies and the data not followed a normal
distribution, i.e. other type of statistical testing
was limited. A signiﬁcant level of P < 0.05 was
used for all statistics.
Figures (n = 18)* 
(MPIs %)
Pictograms 
(n = 23)* 
(MPIs %)
Tables (n = 77)** 
(MPIs %)
Lists/iterations 
(Total) (n = 577)* 
(MPIs %)
Lists/iterations 
(with hyphens)  
(n = 506)* (MPIs 
%)
Other graphic 
elements 
(n = 534)* (MPIs 
%)
CNS (309 MPIs) 2.3 5.5 13.3 84.8 73.8 61.8
CS (179 MPIs) 1.1 1.1 10.6 92.7 82.1 53.1
MS (163 MPIs) 5.5 2.5 10.4 91.4 80.4 67.5
0
20
40
60
80
100
Figure 1 Percentage of package inserts containing different graphic elements. * The proportion of figures (K–W = 3.677;
P = 0.045), pictograms (K–W = 7.124; P = 0.006), lists/iterations (K–W = 8.759; P = 0.004) and OGE (K–W = 7.115;
P = 0.007) was significantly different between the MPIs of the three therapeutic groups (CNS, CS and MS). ** The
proportion of tables (K–W = 0.670; P = 0.391) was not statistically different between the MPIs of the three therapeutic
groups (CNS, CS and MS)
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Results
Study A – The descriptive study
A total of 651 MPIs were selected and analysed.
The percentages of MPIs containing different
graphic elements in each therapeutic group (CNS,
CS, MS) are presented in the Fig. 1.
The qualitative descriptors of the graphic
elements are presented in Table 1. The
classiﬁcation and distribution of the non-
recommended graphical elements,17,23,24,27,33 i.e.
hyphenated lists (instead of bullet lists), headings
with text boxes, italic, capitalised letters in the
body text, underline and titles of sections not fully
capitalised are presented in the Table 1.
The percentage of MPIs containing illustrations,
tables and lists/iterations in each one of the six
sections of the MPIs (n = 651) is presented in
Fig. 2. The description of the ﬁgures and
pictograms of the sampled MPIs is presented in
Table 2.
Overall, 18 ﬁgures and 23 pictograms were
respectively identiﬁed in 2.8% and 3.5% of the
651 MPIs (Fig. 1). Only three MPIs included
both ﬁgures and pictograms (buprenorphine,
mirtazapine and valsartan) (Table 2). The ﬁgures
were related to medicine taking/usage (e.g.
transdermal patch application), their visual
aspects (e.g. colour, shape and groove of tablets)
and precautions (e.g. risk of bone fracture)
(Table 1). The majority of ﬁgures were related
to oral solid forms47 (e.g. tablets or capsules to
be taken orally), and the rest to oral liquid
forms,47 (e.g. syrups or suspensions to be taken
orally) and to one case of a dermal spray. All
the pictograms were related to taking/usage
instructions and different routes of administration
(e.g. injectable solution, transdermal patch, etc.)
(Tables 1 and 3).
Seventy-seven tables were identiﬁed in 11.8%
of the 651 MPIs. These tables were related to
information on: (1) dosage, (2) adverse reactions
frequency and (3) marketing authorisation holder
(MAH) information (e.g. address) (Table 1).
Besides the low prevalence of ﬁgures, pictograms
and tables in the sampled MPIs (n = 651), these
graphic elements were predominantly used in the
section 3 of the MPIs (i.e. How to <take><use> X)
(Fig. 2). The lists/iterations were more
predominantly used in the section 2 (i.e. What you
need to know before you <take> <use>) and 3
(Fig. 2) in comparison to the other sections.
Study B results: The usability study
The participants’ socio-demographic characteristics
and the percentage of correct answers are
presented in Table 3. All evaluated illustrations
and tables are presented in Appendix B.
Section 1 
(MPIs %)
Section 2 
(MPIs %)
Section 3 
(MPIs %)
Section 4 
(MPIs %)
Section 5 
(MPIs %)
Section 6 
(MPIs %)
Figures (in 2.8% of the 651 MPIs) 0 0.5 1.8 0 0 0.5
Pictograms (in 3.5% of the 651 MPIs) 0 0 3.5 0 0 0
Tables (in 11.8% of the 651 MPIs) 0 0.5 5.5 2.5 1.2 2.2
Lists/iterations (in 88.6% of the 651 MPIs) 16.3 28.9 26.0 12.0 5.1 0.5
0
10
20
30
Figure 2 Percentage of package inserts containing illustrations, tables and lists/iterations (section 1 to 6)
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According to the Kruskal–Wallis statistic results,
the distribution of participants’ age (K–W = 0.068;
P = 0.967), course year (K–W = 4.002; P = 0.135)
and sex (K–W = 3.726; P = 0.155) were not
signiﬁcantly different between the groups, although
there was a slightly higher proportion of females in
the groups of isolated illustrations (82.4%, n = 14)
and text (71.4%, n = 10) in comparison to the
illustrations plus text group (50%, n = 7). On the
contrary, the distribution of the participants’ correct
answers/interpretations for ﬁgures (K–W = 34.137;
P < 0.001) and for pictograms (K–W = 8.819;
P = 0.012) was statistically different, with
signiﬁcantly worse interpretation issues for the
groups of isolated illustrations. In addition, the
answers between the group of isolated illustrations
(ﬁgures only vs. pictograms only), were compared
with signiﬁcantly better interpretation of results for
the group of the isolated pictograms (U = 2210,
P < 0.001).
Legibility problems were detected in the case of
the isolated ﬁgures (Group 1), because
participants’ only adequately interpreted these
isolated graphic elements in approximately half of
the cases (average correct score 50  3%)
(Table 3). The qualitative analysis of participants’
comprehension on these isolated ﬁgures (Group 1),
conﬁrmed that participants were not able to
recognise the presence of a blister (Fig. 3 – do not
break the tablet) or the slot in the middle of the
tablet for easily splitting (Fig. 4 – how to split the
tablet) (Appendix B). As opposed to this, the
participants did not experience any interpretation
problems concerning the ﬁgures associated with
the text excerpts or concerning the texts alone
(Group 2 and 3): 100% of correct interpretations
in both cases were obtained. (Table 3).
Legibility problems were also identiﬁed in the
case of isolated pictograms (correct score
84.3  16%) (Group 1), although the score was not
as low as with the isolated ﬁgures (Table 3).
Considering as well the qualitative analysis of
participants’ comprehension on isolated pictograms
(Group 1), in the case of the pictogram showing the
method for syrup administration (Fig. 5)
(Appendix B), almost all the participants mistook
the bottle syringe adapter for the bottle cap (the
second image in the pictogram). Approximately,
one-third of the participants supposed the container
was used for discarding the remaining syrup in the
syringe or for washing the syringe with alcohol
instead of water (the last image of the pictogram).
Interestingly, a limited number of participants’
comprehension issues were also found in the groups
of pictograms plus text (Group 2) and text only
(Group 3): respectively, 89.3  3.6% and
96.0  3.6 correct scores (Table 3).
In addition, the task of consulting a table to
indicate a speciﬁc dosage (in mL) showed that all
the participants indicated the correct dosage
interval, but only two calculated the exact volume.
Overall, the participants classiﬁed the tables as
good in relation to their layout (Appendix B),
without statistical differences between groups
(K–W = 2.071; P = 0.355).
Discussion
This study comprised two studies, a descriptive
and a usability study. The descriptive study
Table 3 Study B: demographic and interpretation results
Group 1 Illustrations Only Group 2 Illustrations + text Group 3 Text only
Demographic results
Number of undergraduates 17 14 14
Age (mean  SD) 22.5  3 23  3.7 22.6  6.1
Course year (median) 3 2 3
Gender (females) n (%) 14 (82.4%) 7 (50%) 10 (71.4%)
Correct answers (mean  SD) (%)
Figures 50  3 100 100
Pictograms 84.3  16 89.3  3.6* 96.0  3.6*
SD, standard deviation; n, number.
*All the answers were fully correct, with the exception of one case of a blank answer.
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contributed to the increase in the interest in the
use of graphic elements in MPIs, considering the
facts that there is a lack of descriptive studies on
this topic23,48,49 and these documents are
commonly consulted by the patients and general
public.50–52 The usability test raised the question
about the appropriateness of the tested illustrations
and tables for the proper use of medicines, since
some interpretation issues were detected in the
case of the tested graphic elements.
Study A: Describing, characterising and
analysing the graphic elements of MPIs
Although it is widely accepted that the use of visual
information in MPIs improves patients’
comprehension, memorisation, satisfaction and
treatment adherence,11–14,53 a relatively small
number of illustrations were found in the sampled
MPIs. The illustrations were predominantly
identiﬁed in the MPIs of CNS medicines (e.g.
benzodiazepine and antidepressants), which might
be due to the therapeutic speciﬁcities of these
medicines, such as the possibility of dangerous
intoxications accompanied by respiratory
suppression in case of incorrect use. Other
important graphic elements for emphasising and
highlighting portions of text (e.g. bold or list/
iterations with bullets)17,23,24,27,33 were also were
scarcely used in the sampled MPIs. One positive
ﬁnding of this study was that, in accordance to the
international regulations, few non-compliant
graphical elements were identiﬁed, such as headings
with boxes, italics and underline,17,23,24,33 although
the use of graphic elements in the text of the MPIs
is not speciﬁcally determined in the Portuguese
pharmaceutical regulations.36 It is well known that,
the use of uppercase in sections titles, bullet points
and bold font17,23,24,27,33 also contributes to the
proper readability and legibility of the MPIs. On the
other hand, the use of capitalised letters in the body
text, italics or underline promotes the difﬁculty of
word recognition,17,23 thus decreasing the
intelligibility of the MPIs.
There are several studies on how to optimise the
MPIs’ design,23,52,54 for instance, Pander et al.
(Netherlands, 2010) tested the original (154
potential users of medicines) and optimised (164
potential users of medicines) versions of three MPIs
(oxazepam, bisoprolol and rosuvastatin). The
following procedures were used in the optimisation
of the MPIs: the creation of new headings, the
development of a clear headings hierarchy with bold
and letters of different sizes, the use of bullet
information lists and the elimination of some
formats from the body text, such as capitals and
underline. On average, only 75% of the topics were
located in the original versions, while simple design
optimisations led to a 90% correct location of the
information.53 Besides, it is not fully demonstrated
that the use of lists/iterations is more appropriated
than the use of text or tables,55 they were widely
used in the sampled MPIs. The large use of lists/
iterations conﬁrmed that the selected MPIs were
complex documents encompassing a high number
of factual information. Lists/iterations were
frequently used in section 2 (What you need to know
before you <take> <use> X) to present information
on dosage and adverse reactions. According to the
QRD template,32 this section comprises very
diverse issues, such as information on
contraindications, precautions (e.g. pregnant/breast-
feeding women), interactions, effects on the ability
to drive or to use machines, etc. In addition, the
majority of the selected MPIs presented hyphenated
lists, in opposition to the use of bullet points as
recommended by the readability guideline of
EMA.10
Overall, it seemed that the criteria used to
conceive and approve the sampled MPIs were not
homogeneously applied by MAH and medicines
authorities, because the graphic elements were
dissimilarly used in the MPIs of the three
therapeutic groups (SNC, CS, MS), which possibly
inﬂuenced the safe use of the medicines. This is
even more important, knowing that some
Portuguese MPIs are direct translations of MPIs
available in other European countries (e.g.
medicines approved via a centralised
procedure).32,40 Therefore, future research,
speciﬁcally on how to use graphic elements in the
MPIs is recommended.
Study B: The usability of some illustrations and
tables from the sampled MPIs
Besides the fact that a usability proof is required
to approve all MPIs of medicinal products for
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human use in Europe,10 interpretation issues were
identiﬁed in the case of the tested illustrations,
especially in the case of the ﬁgures only, thus
conﬁrming the difﬁculty of selecting appropriate
illustration to use in the MPIs. Furthermore,
databases on validated illustrations to be used in
the health information materials are limited,30,31,56
such as the illustration database of the United
States Pharmacopoeia.56 In fact, the of tested and
validated illustrations to be used in particular
databases for each country is advisable, regarding
the cultural and social differences among
countries. For instance, only some US pictograms
were fully understood by a group of clients of
Portuguese pharmacies.30
Participants’ comprehension of pictograms was
better with statistical signiﬁcance than the
comprehension of ﬁgures, maybe because
pictograms contain more illustrated information and
stepwise explanations than ﬁgures. Nevertheless,
and similarly to previous studies, the participants’
comprehension of illustrations with text were
signiﬁcantly better than illustrations alone.11,14,18
The placement of supplementary information near
the illustrations and not only in the text (e.g. use of
subtitles on critical information directly in the
pictogram) seems important, because this important
information might be skipped in the text and not
correctly interpreted in the pictogram. For instance,
if the important items of information to “not remove
the adapter after the ﬁrst utilisation” or to “use water
as the appropriate liquid to wash the syringe” in the
Valproic Acid MPI text (Appendix B) are skipped
in the text, it is very likely that the pictogram will
not be helpful to avoid the incorrect use of the
medicine.
Usability issues were also identiﬁed in tables.
For instance, the participants’ consultation of
tables associated with the performance of some
simple mathematical operations was not devoid of
interpretation issues, even if the participants were
of high literacy level. Oppositely, the simpler
consultation of tables, i.e. crossing a single row
with a single column without the performance of
mathematical calculations, was not associated with
interpretation issues, which conﬁrms the
importance of developing simple and clear tables.
Considering that the tables with more rows and
columns were probably more complex and difﬁcult
to consult, it seems that the tables with simple
formats are more suitable to be used in health
information material. In this context, it is also
advisable that all the tables should be submitted to
speciﬁc usability tests during their development
and approval stages.
Interestingly, the participants were not too
demanding in relation to tables’ layout and design,
classifying on average as good, even if the two
evaluated tables presented different graphic
characteristics (e.g. number of columns and rows)
(Appendix B). Participants’ opinion on the layout
of these tables was not signiﬁcantly different,
which suggest further studies on the ideal
characteristics of tables.
Study strengths
There are few descriptive studies speciﬁcally on
the graphic elements of the MPIs,23,48,49 and in
particular, studies using a large sample of MPIs.
Some of the analysed MPIs are also available in
other European Countries (e.g. the MPIs of the
medicines approved via a centralised procedure),
which makes the present results interesting to an
international audience.32,47,57 Participants with
high literacy levels are more likely to understand
the visual or written medicine information in
comparison to the low-literate patients and to
avoid issues expected to be common with the
participants of the low educational levels.4,5,8 The
distribution of age, year course and sex was
homogenous between the three groups
(illustrations only, illustrations plus text and text
only) and similar sample sizes were used in
previously published studies.10,11,18,46
Study limitations
Participants with different health conditions and
from different cultural backgrounds were not
included, and a relatively small number of
participants were enrolled in the usability study. In a
more realistic approach, the original MPIs and
packages of medicines (e.g. syrup bottles or outside
packages) should have been used in the usability
study, instead of text transcriptions in a
questionnaire. The use of original materials was not
possible due to logistic reasons. The female
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participants were prevalent in this study, which
might have inﬂuenced the study results.
Triangulation methods to double-check the results
were not performed, such as eye-tracking
studies.58,59
Practical implications
Overall, it is advisable to validate the graphical
content of MPIs, for instance through the formation
of standardised illustrations databases. Speciﬁc
legibility tests to evaluate participants’
comprehension of illustrations and tables, or tests to
detect other typographic issues in the MPIs, e.g.
tests to evaluate the visual perception of words and
forms or the appropriateness of the size and type of
letters,31 are recommended. Besides the speciﬁc
quantitative and qualitative problems on the MPIs
graphical content here identiﬁed, this study raises
the importance of assuring the appropriateness of
the layout and design of all types of written health
materials. In this context, health information
professions must be aware of these requisites when
developing or supervising health related
information. Actually, these professionals should be
involved in the development of validated graphical
health information, for instance contributing to a
standardised illustrations databases.
Also, this study increases the interest of
practitioners, researchers and students from library
and health information on the relevance of MPIs
and their graphical content, thus promoting the
development of new intervention areas in this
sector and contributing to a higher social impact
of the health library related sciences. On the other
hand, public libraries also may index and classify
these type of health documents i.e. consumers
medicine information. As a consequence, the
general public, and particularly those unable to
ﬁnd precise and reliable drug-related information
may beneﬁt from the availability of these
documents in libraries.
Conclusions
Graphic elements that negatively impact the
legibility of the MPIs were detected in this study,
such as the frequent use of hyphenated lists/
iterations and capitalised letters, and the use of
underline and italics in the body text. In addition,
illustrations and tables were scarcely used, which
might have a negative impact in the legibility of
the MPIs. Although the advantage of using
graphic elements speciﬁcally on “how to use the
medicine” is not fully demonstrated, the majority
of the graphic elements were related to this topic.
It is likely that some of the tested illustrations and
tables need to be optimised, since legibility issues
were identiﬁed in the usability study. A revision of
the graphical content of inserts in medicines
packages and the update and enforcement of the
regulations on the use of illustrations or other
graphic elements is needed, including more
rigorous legibility tests before the approval of
MPIs into the market. Moreover, experts in library
and health information should have a more
predominant role in the production, supervision
and indexing of written health materials, such as
MPIs. Therefore, this study highlights the need to
carefully review/assess the MPI’s design and
increase health information experts’ awareness in
this area.
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Appendix A
Checklist
Graphic elements Response options
1. Figures:
Figures presence? No or Yes
In case of Figures presence:
Number of Figures 1 – None figure
2 – One figure
3 – Two figures
Figures location? (by section) MPI section 1–6:
1. What is X (X = medicinal product name) and what is used for;
2. What you need to know before you <take> <use> X;
3. How to <take> <use> X;
4. Possible side effects;
5. How to store X;
6. Contents of the package and other information.
Figures classification
(according Qualitative descriptors)
1 – How to <take> <use>
2 – How it looks like
3 – Precautions
2. Pictograms:a
Pictograms presence? No or Yes
In case of Pictograms presence:
Number of Pictograms 1 – None pictogram
2 – One pictogram
3 – Two pictograms
Pictograms location? (by section) MPI section 1–6
Pictograms classification
(according Qualitative descriptors)
1 – How to <take> <use>
3. Tables:
Tables presence? No or Yes
In case of Tables presence:
Number of Tables 1 – None table
2 – One table
3 – Two tables
Tables location? (by section) MPI section 1–6
Tables classification
(according Qualitative descriptors)
1 – ADR description and frequency
2 – ADR frequency
3 – Precautions
4 – Interactions
5 – Posology
6 – Fargerstr€om Test
7 – Marketing Authorization Holders
(continued)
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Appendix A. (continued)
Graphic elements Response options
4. Lists/Iterations:b
Lists/Iterations presence? Yes or No
In case of Lists/Iterations presence:
Symbol type (in case of Lists/Iterations) 1 – Hyphen
2 – Other
Lists/Iterations location? (by section) MPI section 1–6
N. of MPIs with Lists / Section type 1 – N. of MPIs with Lists in section 1
2 – N. of MPIs with Lists in section 2
3 – N. of MPIs with Lists in section 3
4 – N. of MPIs with Lists in section 4
5 – N. of MPIs with Lists in section 5
6 – N. of MPIs with Lists in section 6
Lists/Iterations classification
(according Qualitative descriptors)
1 – What is used for
2 – Mechanism of action
3 – Do not use
4 – Take special care
5 – Interactions
6 – Pregnancy
7 – Breastfeeding
8 – Fertility
9 – Driving
10 – Posology
11 – Overdose
12 – Laboratorial tests (or other routine examinations)
13 – Administration form
14 – ADR
15 – Conservation
16 – Packaging
17 – Physical aspect
18 – Composition
5. Other Graphic Elementsc
OGE presence? No or Yes
In case of OGE presence:
OGE location? (by section) MPI section 1–6
Number of MPIs
with OGE / number of sections
1 – N. of MPIs with OGE in one section
2 – N. of MPIs with OGE in two sections
3 – N. of MPIs with OGE in three sections
4 – N. of MPIs with OGE in four sections
5 – N. of MPIs with OGE in five sections
6 – N. of MPIs with OGE in six sections
OGE classification
(according Qualitative descriptors)
1 – Bold
2 – Text box
3 – Italics
4 – Uppercase
5 – Graphic elements associations (mixture of the previous)
6 – Underline
7 – Use of one graphic element to highlight and/or
summarize a key information
6. MPI Title
Capital letters (all title) No or Yes
Capital letters at the beginning of the title No or Yes
Mixture of upper with lowercase No or Yes
aOGE, other graphic elements; MPI, medicine package insert; ADR, adverse drug reactions.
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aPictogram: a pictorial representation formed at least for two figures.
bLists/Iterations: lists of words preceded by hyphens, bullets points or other, e.g. lists of adverse reaction.
cOGE: bold font, italics, underline, capitalized letters in the body text, headings with text boxes, associations of the previous
graphic elements, other graphic elements used to highlight information, and the case format of the section titles (uppercase,
lowercase or both).
Appendix B
Questions, illustrations and tables used in the usability test
Figure 3 is available Infomed37 on-line in a Mirtazepine medicine package insert (MPI).
Question: Knowing that a tablet is represented in the ﬁgure, please give (in few words) your personal
opinion about the interpretation of the ﬁgure
Figure 4 is available on-line Infomed37 in an Escitalopram MPI.
Question: Knowing that a pill is represented in the ﬁgure, please give (in few words) your personal
opinion about the interpretation of the ﬁgure
Figure 3 Do not break the tablet
Figure 4 How to split the pill
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Figure 5 is available on-line Infomed37 in a Valproic acid MPI.
Question: Knowing that the administration of syrup is represented in the illustration; please give (in
few words) your personal opinion about the interpretation of each one of the 8 ﬁgures
Figure 6 is available on-line Infomed37 in a Diclofenac MPI.
Question: Knowing that a transdermal patch is represented in the illustration, please give (in few
words) your personal opinion about the interpretation of each one of the 4 ﬁgures
1 2 3 4
5 6 7 8
Figure 5 Pictogram: syrup administration
Figure 6 Pictogram: Transdermal system application (Step 1 of 4)
Table B.1 Oral suspension dosage instructions.
Age and body weight Dosage
Children from 3–6 months (body weight of about 5–7.6 kg) May be taken a dose of 2.5 ml, 3 times in 24 hours
Children from 6–12 months (body weight of about 7.7–9 kg) May be taken a dose of 2.5 ml, 3–4 times in 24 hours
Children from 1–3 years (body weight of about 10–15 kg) May be taken a dose of 5 ml, 3 times in 24 hours
Children from 4–6 years (body weight of about 16–20 kg) May be taken a dose of 7.5 ml (5 ml + 2.5 ml),
3 times in 24 hours
Children from 7–9 years (body weight of about 21–29 kg) May be taken two doses of 5 ml, 3 times in 24 hours
Children from 10–12 years (body weight of about 30–40 kg) May be taken three doses of 5 ml, 3 times in 24 hours
A Portuguese version of Table B.1 is available on-line Infomed5 in an Ibuprofen MPI.
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Questions:
a) Rate the tables in relation to its general appearance (organization of the information in the table and
layout). Mark with a cross the answer that you consider more adequate.
Table B.2 Syrup dosage instructions.
Age Body Weight
Dosage of Paracetamol
for each administration
Volume of Paracetamol
for each administration
Maximum Dose of
Paracetamol in 24 hours
3–6 months Up to 7 kg 70–100 mg 1.75–2.5 ml 350 mg
7 months to 1 year 8–10 kg 100–150 mg 2.5–3.75 ml 500 mg
2–3 years 11–15 kg 150–200 mg 3.75–5 ml 750 mg
4–6 years 16–22 kg 200–300 mg 5–7.5 ml 1000 mg
7–9 years 23–30 kg 300–500 mg 7.5–12.5 ml 1500 mg
10–12 years 31–40 kg 400–600 mg 10–15 ml 2000 mg
More than 12 years More than 41 kg 500–1000 mg 12.5–25 ml 3000 mg
A Portuguese version of Table B.2 is available on-line Infomed5 in a Paracetamol MPI.
Very Good □
Good □
Medium □
Bad □
Very Bad □
Table B.2:
Very Good □
Good □
Medium □
Bad □
Very Bad □
b) Please consult Table B.2. How many syrup is
needed to a children with 8 years old and 25 kg (in a
single administration)? Please answer giving the exact
volume (not respond within a volume range).
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